Nov 12, 2019 / 08:50PM GMT
Evan David Seigerman - Crédit Suisse AG - Research Division - VP & Senior Equity Research Analyst
We're ready. Hi, there. My name is Evan Seigerman, and I'm the senior large-cap biotechnology analyst here at Crédit Suisse. And with me today, we have Neurocrine Biosciences. And representing Neurocrine, we have Matt Abernethy, the CFO. Before we get started, I think you have a few comments.
Matthew C. Abernethy - Neurocrine Biosciences, Inc. - CFO
Yes, sure. Thanks, Evan, and thank you to you and Crédit Suisse for inviting us to this year's health care conference.
Before I begin, I will be making forward-looking statements. So I would direct you to our latest SEC filings for the related risk factors and uncertainties associated with our company and then also our industry. Evan, before we jump into the Q&A, I thought it may make sense for me to just give a brief overview of who Neurocrine is for those not as familiar with our story.
So Neurocrine has been around for quite some time, over 25 years, with a
Neurocrine Biosciences Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 13, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers